Compare IDT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | CTMX |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | 1925 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 977.1M |
| IPO Year | N/A | 2015 |
| Metric | IDT | CTMX |
|---|---|---|
| Price | $51.84 | $4.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $80.00 | $12.10 |
| AVG Volume (30 Days) | 88.6K | ★ 3.7M |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | ★ $15.10 | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $45.72 | $0.91 |
| 52 Week High | $71.12 | $8.21 |
| Indicator | IDT | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 41.91 |
| Support Level | $46.85 | $3.94 |
| Resistance Level | $52.57 | $4.33 |
| Average True Range (ATR) | 1.33 | 0.26 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 63.57 | 16.06 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.